Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Renal Cell Carcinoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

featured
Published in Renal Cell Carcinoma

Expert Opinion / Cases · June 16, 2015

Amygdala Metastases in 61 Year Old Male With Longstanding History of Metastatic Renal Cell Carcinoma

Written by
Heather R Greene MSN, FNP, AOCNP

 

Additional Info

Disclosure statements are available on the authors' profiles:

Discuss This item Follow

No comments yet, be the first to start the discussion!

  • Heather Greene MSN, FNP, AOCNP

    Heather R Greene MSN, FNP, AOCNP

    Jun 15, 2015

    He has now had Gamma Knife radiosurgery to the single left uncus metastases. Open biopsy of the left femoral lesion is positive for renal cell carcinoma. Restaging CT scans showing mild progression of the right hilar adenopathy and multiple bone metastases with possible encroachment on the cord at T8. A lesion at L2 also shows extension into the spinal canal. He has no neurological symptoms. The plan was to start axitinib prior to receiving these recent results.

    Does this change your initial treatment strategy?


  • Bradley Somer MD

    Bradley G. Somer MD

    Jun 16, 2015

    Either axitinib or everolimus are potential options at this point. However, axitinib is a multiple tyrosine kinase inhibitor, which includes inhibiting VEGF and thus may cause impaired wound healing. Since he has had recent hip surgery and may potentially need additional surgery for the new spinal met, everolimus, which does not have the wound healing issues, may be the better choice. I would also recommend sending tissue for molecular profiling for future treatment considerations.


  • Apr 24, 2024

    Pending Moderator approval.
    Delete

Further Reading